Dr. Finn Discusses Research in Triple-Negative Breast Cancer

Richard S. Finn, MD
Published: Tuesday, Nov 19, 2013

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses current research in triple-negative breast cancer (TNBC).

TNBC is an area of unmet need, Finn says, and is defined by the absence of a druggable target and represents many molecular subtypes in and of itself. Research has been conducted in TNBC looking at Src inhibition and PARP inhibition.

One PARP inhibitor, BMN 673, looks particularly potent for BRCA-mutated breast cancer. Still, Finn says, there remains a need to understand the biology of TNBC.

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses current research in triple-negative breast cancer (TNBC).

TNBC is an area of unmet need, Finn says, and is defined by the absence of a druggable target and represents many molecular subtypes in and of itself. Research has been conducted in TNBC looking at Src inhibition and PARP inhibition.

One PARP inhibitor, BMN 673, looks particularly potent for BRCA-mutated breast cancer. Still, Finn says, there remains a need to understand the biology of TNBC.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x